Key result
Upregulated exosomal hsa_circ_0075269 identifies chronic coronary syndrome with an AUC of ~0.76.
Why the study?
Circular RNA is involved in the pathogenesis of cardiovascular disease, but it remained unclear whether exosome-carried circRNAs can serve as diagnostic biomarkers for chronic coronary syndrome.
Do circulating plasma exosomal circRNAs (exo-hsa_circ_0075269 and exo-hsa_circ_0000284) accurately discriminate patients with chronic coronary syndrome from patients with non-cardiac chest pain?
Case-Control (n=218)
No
Do circulating plasma exosomal circRNAs (exo-hsa_circ_0075269 and exo-hsa_circ_0000284) accurately discriminate patients with chronic coronary syndrome from patients with non-cardiac chest pain?
Plasma exosomal hsa_circ_0075269 and hsa_circ_0000284 are significantly upregulated in patients with chronic coronary syndrome and show moderate diagnostic potential as non-invasive biomarkers, particularly exo-hsa_circ_0075269 (AUC 0.761).
Answers are grounded in this paper and cite their sources.
Exosomal circRNAs merit further biomarker investigation in chronic coronary syndrome but should not yet change practice; prospective validation trials are required.
Circular RNA (circRNA) has been reported to be involved in the pathogenesis of cardiovascular disease; however, it is unclear whether circRNA carried by exosomes (exos) can be used as biomarkers for chronic coronary syndrome (CCS). High-throughput sequencing was carried out in the plasma exosomal RNA of 15 CCS patients and 15 non-cardiac chest pain patients (NCCP, control group) to screen for differentially expressed circRNAs. Selected differentially expressed exo-circRNAs were further verified by real-time polymerase chain reaction in a small-sample cohort and a large-sample cohort. A total of 276 circRNAs were differentially expressed in the plasma exosomes of CCS patients, with 103 up-regulated and 173 down-regulated. Among the 103 up-regulated circRNAs, 5 circRNAs with high expression levels were selected for validation. Real time quantitative PCR of the first and second validation cohort demonstrated that exo-hsa_circ_0075269 and exo-hsa_circ_0000284 were significantly up-regulated in patients with CCS. Circulating exo-hsa_circ_0075269 and exo-hsa_circ_0000284 yielded the area under the curve values of 0.761 (p < 0.001, 95%CI = 0.669, 0.852) and 0.623 (p = 0.015, 95%CI = 0.522, 0.724) for CCS, respectively, by ROC curve analysis. In conclusion, the expression profile of circRNA in plasma exosomes of patients with CCS was significantly different from that of the control group. Plasma exo-hsa_circ_0075269 and exo-hsa_circ_0000284 have the potential to be new biomarkers for CCS.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) conducted a case-control in Chronic coronary syndrome (CCS) (n=218). Circulating plasma exosomal circRNAs (exo-hsa_circ_0075269 and exo-hsa_circ_0000284) vs. Non-cardiac chest pain (NCCP) patients with normal coronary angiography was evaluated on Diagnostic accuracy (Area Under the ROC Curve [AUC]) of circulating exo-hsa_circ_0075269 for chronic coronary syndrome in the second validation cohort (AUC 0.761, 95% CI 0.669, 0.852, p=< 0.001). Circulating exosomal hsa_circ_0075269 and hsa_circ_0000284 were upregulated in chronic coronary syndrome patients, yielding diagnostic AUCs of 0.761 and 0.623, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: